Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Biomea Fusion (BMEA) to $19 from $10 and keeps an Overweight rating on the shares. The firm notes Biomea reported Q3 earnings and provided a pipeline update. Most notably, Biomea is now specifically guiding towards Phase II topline readouts in both T2D and T1D in December.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: